Successful treatment of methicillin-resistant Staphylococcus aureus osteomyelitis with combination therapy using linezolid and rifampicin under therapeutic drug monitoring

Journal of Infection and Chemotherapy

Volumn 22, Issue 5, 2016, Pages 331-334

  Ashizawa, Nobuyuki ^a   Tsuji, Yasuhiro ^a   Kawago, Koyomi ^a   Higashi, Yoshitsugu ^a   Tashiro, Masato ^a   Nogami, Makiko ^a   Gejo, Ryuichi ^a   Narukawa, Munetoshi ^a   Kimura, Tomoatsu ^a   Yamamoto, Yoshihiro ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Co administration; Linezolid; Methicillin resistant Staphylococcus aureus; Osteomyelitis; Rifampicin; Therapeutic drug monitoring

Indexed keywords

BONE CEMENT; DAPTOMYCIN; HABEKACIN; LINEZOLID; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

AGED; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM ISOLATE; BONE MARROW; CASE REPORT; DEVICE REMOVAL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MONITORING; EFFUSION; FEMALE; FEVER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFECTIOUS ARTHRITIS; KNEE OSTEOARTHRITIS; LEUKOCYTE COUNT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; OSTEOMYELITIS; SKIN FISTULA; SURGICAL INFECTION; TENDON RUPTURE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TOTAL KNEE REPLACEMENT; WOUND FLUID; BLOOD; COMBINATION DRUG THERAPY; KNEE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; PATELLA; PATHOLOGY; STAPHYLOCOCCAL INFECTIONS;

AGED; ANTI-BACTERIAL AGENTS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KNEE; LINEZOLID; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OSTEOMYELITIS; PATELLA; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS;

EID: 84951748013     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2015.11.012     Document Type: Article

References (23)

1. Liu C., Bayer A., Cosgrove S.E., Daum R.S., Fridkin S.K., Gorwitz R.J., et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011, 52:18-55.
2. Vinh D.C., Rubinstein E. Linezolid: a review of safety and tolerability. J Infect 2009, 59:59-74.
3. Takahashi Y., Takesue Y., Nakajima K., Ichiki K., Tsuchida T., Tatsumi S., et al. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother 2011, 17:382-387.
4. Pea F., Viale P., Cojutti P., Del Pin B., Zamparini E., Furlanut M. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother 2012, 67:2034-2042.
5. Matsumoto K., Shigemi A., Takeshita A., Watanabe E., Yokoyama Y., Ikawa K., et al. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients. Int J Antimicrob Agents 2014, 44:242-247.
6. Darley E.S., MacGowan A.P. Antibiotic treatment of gram-positive bone and joint infections. J Antimicrob Chemother 2004, 53:928-935.
7. Majcher-Peszynska J., Haase G., Sass M., Mundkowski R., Pietsch A., Klammt S., et al. Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections. Eur J Clin Pharmacol 2008, 64:1093-1100.
8. Sia I.G., Berbari E.F. Infection and musculoskeletal conditions: osteomyelitis. Best Pract Res Clin Rheumatol 2006, 20:1065-1081.
9. Daver N.G., Shelburne S.A., Atmar R.L., Giordano T.P., Stager C.E., Reitman C.A., et al. Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. J Infect 2007, 54:539-544.
10. Dombrowski J.C., Winston L.G. Clinical failures of appropriately-treated methicillin-resistant Staphylococcus aureus infections. J Infect 2008, 57:110-115.
11. Pea F., Furlanut M., Cojutti P., Cristini F., Zamparini E., Franceschi L., et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother 2010, 54:4605-4610.
12. Weigelt J., Itani K., Stevens D., Lau W., Dryden M., Knirsch C., et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005, 49:2260-2266.
13. Lovering A.M., Zhang J., Bannister G.C., Lankester B.J., Brown J.H., Narendra G., et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002, 50:73-77.
14. Tsuji Y., Hashimoto W., Taniguchi S., Hiraki Y., Mizoguchi A., Yukawa E., et al. Pharmacokinetics of linezolid in the mediastinum and pleural space. Int J Infect Dis 2013, 17:1060-1061.
15. Gee T., Ellis R., Marshall G., Andrews J., Ashby J., Wise R. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001, 45:1843-1846.
16. Attassi K., Hershberger E., Alam R., Zervos M.J. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002, 34:695-698.
17. Nukui Y., Hatakeyama S., Okamoto K., Yamamoto T., Hisaka A., Suzuki H., et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother 2013, 68:2128-2133.
18. Gebhart B.C., Barker B.C., Markewitz B.A. Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy 2007, 27:476-479.
19. Jacqueline C., Caillon J., Le Mabecque V., Miegeville A.F., Donnio P.Y., Bugnon D., et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother 2003, 51:857-864.
20. Swoboda S., Ober M.C., Lichtenstern C., Saleh S., Schwenger V., Sonntag H.G., et al. Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol 2010, 66:291-298.
21. Tsuji Y., Tashiro M., Ashizawa N., Ota Y., Obi H., Nagura S., et al. Treatment of mediastinitis due to methicillin-resistant Staphylococcus aureus in a renal dysfunction patient undergoing adjustments to the linezolid dose. Intern Med 2015, 54:235-239.
22. Tsuji Y., Yukawa E., Hiraki Y., Matsumoto K., Mizoguchi A., Morita K., et al. Population pharmacokinetic analysis of linezolid in low body weight patients with renal dysfunction. J Clin Pharmacol 2013, 53:967-973.
23. Welshman I.R., Sisson T.A., Jungbluth G.L., Stalker D.J., Hopkins N.K. Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm Drug Dispos 2001, 22:91-97.